D1
Receiving log and vial labels
Receiving record DEMO-RCV-26-007 · 17 September 2026
All companies, records, identifiers, methods and values in this packet are fictional. The example models document review for a teaching lab.
The lab received three vials in one shipment. The receiving technician copied the visible fields below. The stock IDs were assigned on arrival. No photograph or packing list with vial-to-lot mapping is attached.
| Label field | Vial A | Vial B | Vial C |
|---|---|---|---|
| Material | TP-04 training peptide | TP-04 training peptide | TP-04 training peptide |
| Catalog | TP04-5 | TP04-5 | TP04-5 |
| Supplier lot | DEMO-TP-041 | DEMO-TP-042 | Unreadable |
| Nominal fill | 5 mg/vial | 5 mg/vial | 5 mg/vial |
| Receiving stock ID | R-241 | R-242 | R-243 |
Files received
D2 and D3 came in the supplier’s shipment email. D4 arrived in a separate internal forwarding message. No submission form, sample-label photo or sample-to-lot cross-reference accompanies D4.
Decision rule for this exercise
Record a vial as documented for the exercise when its material and lot match a CoA and all three reported results meet their stated criteria. Record a hold for a result when a matched CoA has a result outside its criterion. Record a hold for traceability when the vial-to-lot link is missing. Document any outstanding follow-up separately.
These are classroom record statuses. They describe the available evidence for the exercise.
D2
Supplier certificate of analysis
Certificate DEMO-COA-041 · Revision 1
Fictional supplier document. Created for a classroom exercise.
| Field | Certificate entry |
|---|---|
| Issuer | Example Teaching Materials Unit (fictional) |
| Material / catalog | TP-04 training peptide / TP04-5 |
| Supplier lot | DEMO-TP-041 |
| Sample described | One vial selected by the issuer from lot DEMO-TP-041 |
| Date tested / date issued | 10 September 2026 / 12 September 2026 |
Test results
| Attribute and method | Stated criterion | Reported result |
|---|---|---|
| Intact-mass agreement · LC-MS, deconvoluted neutral average mass | 1124.10–1125.10 Da | 1124.71 Da |
| Main peak · RP-HPLC-UV, relative integrated area | ≥ 98.0 area % | 98.6 area % |
| Peptide content · calibrated LC-UV assay against a reference standard | 4.50–5.50 mg/vial | 4.92 mg/vial |
Main peak area uses the main integrated peak area divided by the total integrated area under this LC-UV method. The content result uses a separate calibrated assay and is reported in mg/vial.
The results apply to the described test sample. The CoA records the issuer’s lot-level statement. It gives no receiving stock ID.
D3
Supplier certificate of analysis
Certificate DEMO-COA-042 · Revision 1
Fictional supplier document. Created for a classroom exercise.
| Field | Certificate entry |
|---|---|
| Issuer | Example Teaching Materials Unit (fictional) |
| Material / catalog | TP-04 training peptide / TP04-5 |
| Supplier lot | DEMO-TP-042 |
| Sample described | One vial selected by the issuer from lot DEMO-TP-042 |
| Date tested / date issued | 10 September 2026 / 12 September 2026 |
Test results
| Attribute and method | Stated criterion | Reported result |
|---|---|---|
| Intact-mass agreement · LC-MS, deconvoluted neutral average mass | 1124.10–1125.10 Da | 1124.55 Da |
| Main peak · RP-HPLC-UV, relative integrated area | ≥ 98.0 area % | 99.2 area % |
| Peptide content · calibrated LC-UV assay against a reference standard | 4.50–5.50 mg/vial | 4.32 mg/vial |
Main peak area uses the main integrated peak area divided by the total integrated area under this LC-UV method. The content result uses a separate calibrated assay and is reported in mg/vial.
The results apply to the described test sample. The CoA records the issuer’s lot-level statement. It gives no receiving stock ID.
D4
External laboratory report
Report DEMO-LAB-2651 · Revision 1
Fictional laboratory report and forwarding note. Created for a classroom exercise.
| Field | Report entry |
|---|---|
| Issuer | Example Instructional Analytics (fictional) |
| Laboratory sample ID | DEMO-EXT-714 |
| Submitter reference | TR-714 |
| Received description | One vial, marked TP04-5 |
| Supplier lot / receiving stock ID | Both fields blank |
| Date received / date issued | 18 September 2026 / 22 September 2026 |
Reported observations
| Attribute and method | Reported result |
|---|---|
| Intact-mass agreement · LC-MS, deconvoluted neutral average mass | 1124.68 Da |
| Main peak · RP-HPLC-UV, relative integrated area | 99.1 area % |
| Peptide content in mg/vial | Outside the report’s test scope |
The laboratory lists no acceptance criteria and gives no conformity verdict. It reports results for the received sample DEMO-EXT-714.
Internal forwarding note · 23 September 2026
“I think this might be Vial B because it came from the same delivery. Can you file it against B?”
The forwarded material includes the report alone. The note contains no contemporaneous sample mapping or label image.